Accentia Biopharmaceuticals, Inc | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Accentia Biopharmaceuticals, Inc

An SI Board Since January 2008

Posts	SubjectMarks	Bans	Symbol
8	2	0	ABPI

Emcee: John McCarthy	Type: Unmoderated

Introduction Market Data Compact

Home Page
accentia.net

BIOVAXID™
BIOVAXID™ Cancer Vaccine
Non-Hodgkin's Lymphoma – Physician Information
accentia.net
accentia.net

List of Clincial Trials
accentia.net

Product Pipeline
accentia.net

Yahoo post

It looks like the move has started (earlier than I expected). There are some very strong catalysts going into spring 2008 that could give this some legs:

1. The unblinding of the SinuNase Phase III data.

2. The unblinding of the BiovaxID Phase III data.

3. Pending good results for SinuNase, the announcement of a big pharma partnership.

4. Pending good results for SinuNase, the filing for accelerated FDA approval.

5. Pending good results for BiovaxID, the filing for conditional FDA approval.

6. The start of the Revimmune Phase III trial.

7. The announcement of a partner for the Revimmune trial.

messages.finance.yahoo.com

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
8	Here is the Biovest CC from yesterday. vcall.com Looks like they picked up the	kenhott	-	7/22/2008
7	Biovest Reports Results for Patients Treated with Anti-Cancer Vaccine: BiovaxID(	kenhott	-	7/21/2008
6	from seeking alpha: On Tuesday, Accentia Biopharmaceuticals (ABPI) reported th	mopgcw	-	6/19/2008
5	Complete molecular remissions induced by patient-specific vaccination plus granu	John McCarthy	-	1/1/2008
4	National Cancer Institute-Frederick, Building 567, Room 203, Frederick, MD 21702	John McCarthy	-	1/1/2008
3	Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular	John McCarthy	-	1/1/2008
2	Key Statistics from Yahoo ... finance.yahoo.com	John McCarthy	-	1/1/2008
1	Accentia Biopharma to report positive data on three therapeutics in 1H08 Decembe	John McCarthy	-	1/1/2008

Go to reply# or date (mm/dd/yy):